Salarius Pharmaceuticals Inc is a clinical-stage oncology company. The Company specializes in targeting the epigenetic causes of cancers and developing treatments for patients. Salarius Pharmaceuticals serves patients and customers in the State of Texas.

Current Report (Form 8-K | Period ending 2024-12-20)

S-1 | IPO Registration

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Salarius Pharmaceuticals (SLRX US)

Current Report (Form 8-K | Period ending 2024-12-20)

S-1 | IPO Registration

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-09-27)

Current Report (Form 8-K | Period ending 2024-08-13)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)